Project Grant R01CA295683
Award Date
12/13/24
Completion Date
11/30/29
Dollars Obligated
$704K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $549,536 to the Trustees of Dartmouth College to develop an innovative 3D wearable near-infrared (NIR) spectral tomography system. The objective is to create a clinical platform capable of early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The proposed technological innovations focus...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $419,133 to the Massachusetts Institute of Technology (MIT) to develop the AscitesPredict technology. This "ex vivo tumor biosensor" platform uses single-cell technologies and machine learning to evaluate cell identities and therapeutic sensitivities from patient ascites samples, which can provide a readily accessible alternative to tumor biopsies. The...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research aimed at improving chemoradiotherapy for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The key focus is on understanding how fractionated radiation therapy affects the tumor microenvironment to influence drug delivery, and testing whether long-circulating chemotherapy can synergistically improve responses...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop deep learning models to predict response to immune checkpoint inhibitor (ICI) therapy in patients with brain metastases. The total funding for this 4-year award is $194,022. The key objectives are to: 1) Develop a deep learning model using pre-treatment brain MRI...
This federal Project Grant award, totaling $4,991,950.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding the "INVESTIGATION OF A MULTICANCER EARLY DETECTION TEST IN A HIGH-RISK MILITARY POPULATION" at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to develop and evaluate a novel multicancer early detection test for use within a high-risk military...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to the Baylor College of Medicine to conduct research aimed at identifying new predictors of response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The key objectives are to: 1) Identify intratumoral microbiome profiles predictive of ICI response using whole-metagenome sequencing; 2) Characterize spatial immune...
The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, will fund the development and pilot testing of the Integrated Cancer Awareness Network (ICAN), an innovative mHealth platform. ICAN will provide cancer risk, symptom, and screening education to...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $226,704 to the Dartmouth-Hitchcock Clinic, with a performance period from January 1, 2025 to December 31, 2026. The grant supports research to develop a magnetic nanoparticle heating system that uses low-frequency alternating magnetic fields to deposit energy into the nanoparticles more efficiently while minimizing heating of surrounding normal tissue. This system aims to...